A 50-year-old patient had an early biochemical recurrence after radical prostatectomy and androgen deprivation therapy and castration. An anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid positron emission tomography/computed tomography scan showed a single pelvic lymph node metastasis. The patient was given volume-modulated arc therapy with a cumulative dose of 50 Gy for the volume with pelvic lymph nodes and 78 Gy to the boost volume for the lymph node metastasis. He experienced only a transitory mild toxicity from the rectum and the urinary bladder and had a partial remission for 16 months.
SchröderF.H., KurthK.H., FossaS.D., HoekstraW., KarthausP.P., De PrijckL., ColletteL.: Early versus delayed endocrine treatment of T2-T3 pN1–3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).Eur Urol, 55: 14–22, 2009.
2.
SteuberT., BudäusL., WalzJ., ZornK.C., SchlommT., ChunF., AhyaiS., FischM., SauterG., HulandH., GraefenM., HaeseA.: Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.BJU Int, 107: 1755–1761, 2011.
3.
MessingE.M., ManolaJ., YaoJ., KiernanM., CrawfordD., WildingG., di'SantAgneseP.A., TrumpD.; Eastern Cooperative Oncology Group study EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.Lancet Oncol, 7: 472–479, 2006.
4.
JohnstoneP.A.S., AssikisV., GoodmanM., WardK.C., RiffenburghR.H., MasterV.: Lack of survival benefit of post-operative radiation therapy for prostate cancer patients with positive lymph nodes.Prostate Cancer Prostatic Dis, 10: 185–188, 2007.
5.
GranforsT., ModigH., DamberJ.E., TomicR.: Long-term follow-up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.J Urol, 176: 544–547, 2006.
6.
LawtonC.A., WinterK., GrignonD., PilerichM.V.: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31.J Clin Oncol, 23: 800–807, 2005.
7.
BrigantiA., KarnesR.J., Da PozzoL.F., CozzariniC., CapitanioU., GallinaA., SuardiN., BianchiM., TutoloM., SaloniaA., Di MuzioN., RigattiP., MontorsiF., BluteM.: Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–T4 pN+ prostate cancer: results of a matched analysis.Eur Urol, 59: 832–840, 2011.
8.
FuccioC., CastelluciP., SchiavinaR., GuidalottiP.L., GavaruzziG., MontiniG.C., NanniC., MarzolaM.C., RubelloD., FantiS.: Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.Eur J Radiol, 81: e893–e896, 2012.
9.
SchusterD.M., Savir-BaruchB., NiehP.T., MasterV.A., HalkarR.K., RossiP.J., LewisM.M., NyeJ.A., YuW., BowmanF.D., GoodmanM.M.: Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.Radiology, 259: 852–861, 2011.
HeidenreichA., BastianP.J., BellmuntJ., BollaM., JoniauS., MasonV., MatveevV., MottetN., van der KvastT.H., WiegelT.T., ZattoniF., members of the European Association of Urology (EAU) Guidelines Office: Guidelines on Prostate Cancer. In: EAU Guidelines, edition presented at the 27th EAU Annual Congress, Paris 2012. ISBN 978-90-79754-83-0.
12.
JohannessenD.C., KleppO., BergeV., LillebyW., BrenhovdB., AngelsenA., for Directorate of Health: National management program with guidelines for diagnostics, treatment and follow-up of prostate cancer.Section for hospital services.Norwegian Directorate of Health, Oslo, 1999: 2–127 (in Norwegian).
13.
KubanD.A., LevyL.B., CheungM.R., LeeA.K., ChoiS., FrankS., PollackA.: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer.Who dies of disease? Int J Radiat Oncol Biol Phys, 79: 1310–1317, 2011.
